AACHEN, Germany, Feb. 28, 2008 (PRIME NEWSWIRE) -- The biopharmaceutical company PAION AG (Frankfurt:PA8) (Prime Standard) today announced that its drug candidate Solulin has been successfully tested in a first-in-man study. The substance was safe and well tolerated. Furthermore, laboratory tests confirmed for a first time in humans the pharmacological profile observed in preclinical studies. At the same time, these tests did not reveal any relevant change in factors seen as key indicators for an increased bleeding propensity.
